Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis - Scorecard - MDSpire

Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis

  • By

  • Jiani Chen

  • Tong Sun

  • Weili Luo

  • Chengyang Cao

  • Jiaqin Xu

  • Jiaxi Chen

  • June 4, 2026

  • 0 min

Share

Clinical Scorecard: Distinct Plasma Metabolomic and Lipidomic Profiles Linked to Lack of Response in Rheumatoid Arthritis Treatment

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with rheumatoid arthritis, particularly those with inadequate treatment responses.
Care Setting

Key Highlights

  • Identification of 12 core metabolites and lipids associated with treatment non-response.
  • Machine learning models achieved AUC values exceeding 0.90 for distinguishing treatment responses.
  • Significant correlations observed between identified features and high disease activity.
  • Metabolic changes may serve as valuable markers for treatment response.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor metabolic changes as potential indicators of treatment efficacy over time.

      Risks

        Patient & Prescribing Data

        Biological agents and targeted therapeutics have altered disease course for some RA patients, particularly in those who do not respond to first-line therapies.

        Clinical Best Practices

        • Implement non-invasive diagnostic methods with high sensitivity and specificity for timely prognostic assessments.
        • Utilize LC-MS-based metabolomics and lipidomics for comprehensive profiling in RA management, integrating these into routine clinical assessments.

        Related Resources & Content

        Original Source(s)

        Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis

        • by Jiani Chen, Tong Sun, Weili Luo, Chengyang Cao, Jiaqin Xu, Jiaxi Chen

        • June 4, 2026

        Related Content

        RA Prescribing Patterns Shift Over 15 Years

        An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

        Thyroid hormones and thyroid hormone sensitivity indices correlate with volumetric bone mineral density and vertebral fracture risk among the osteoporotic population in northern China

        Comprehensive analysis of the TGF-β signaling pathway: molecular mechanisms, disease drivers, and frontiers in clinical translation